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➢Synthesis of Palindromic, Chimeric THEV/OSW-1 and THEV/25-OH Scaffolds
➢ THEV: A Minor Enviroxime-like Compound
THEV has been identified as an OSBP ligand with comparable affinity to OSW-1. Although both compounds
share a steroid core, they significantly differ in their decorative moieties. The understood OSW-1 binding
mode places the A-Ring 3-hydroxy at the bottom of the binding pocket. This binding mode is likely not
possible for THEV due to the THP group on the A-ring. We suspect the D-ring 17-OH present on THEV
serves the purpose of the 3-OH on OSW-1. This would imply the THEV binding modality is “Palindromic”
compared to OSW-1. To assess this hypothesis and further elucidate ligand biding modalities to OSBP,
chimeric scaffolds with palindromic assembly will be synthesized and their binding affinity to OSBP will be
determined via a radioligand binding assay.
➢ OSBP as a Prophylactic Antiviral Drug Target
The role of OSBP in positive-sense ssRNA viral replication has recently been demonstrated. In this role,
OSBP is recruited by the viral 3A protein to provide cholesterol to the developing viral replication organelle
(VRO). OSW-1, an OSBP high-affinity natural product ligand, has been shown to initiate OSBP degradation
via the proteosome and elicits a prolonged repression via a currently unknown mechanism. Prolonged
OSBP repression is then able to reduce viral load in vitro for several enteroviruses. OSBP is known to bind
many different ligands, many of which also target the OSBP homologue ORP4. Although short-term OSBP
repression does not show detrimental effects in vitro, ORP4 is essential for several cell types. Because of
this, more information about ligand binding modalities to OSBP is necessary to determine if this interesting
protein can serve as a prophylactic antiviral drug target.
➢Binding Study Format Measuring the interaction of ligand to protein via a Competitive Binding Assay format
Current Progress and Future Directions
➢Target Primary Compounds Compounds meant to examine the primary hypothesis
➢Target Secondary Compounds Compounds meant to modulate binding compared to Primary Compounds
Increasing concentrations of Test Ligand are incubated with constant concentration of Measurable Ligand and protein. After incubation, 
samples are combined with scintillation fluid. Radiation from residual Measurable Ligand causes the scintillation fluid to emit light, which is 
then detected. If a Test Ligand binding affinity is comparable to or better than the Measurable Ligand, a binding curve can be constructed. 
The binding curve enables the calculation of a binding constant, which is a normalized value comparable between different test ligands. 
➢ 20 of the current 40 proposed compounds have been 
synthesized. 
➢ Binding studies will begin with THEV and its analogues, then 
continue with additional ligands as synthesis is completed.
➢ Future directions may see other biological assay methods 
employed (e.g. Cytotoxicity) as well as additional ligand 
development. 
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Tritiated 25-hydroxycholesterol ([3H]-
25OH) serves as the Measurable 
Ligand. 25-OH is an endogenous high-
affinity OSBP ligand (KD=22+/- 5 nM)
3) Cell Reports., 2015, 10, 600-615
